Diagnosis and management of high platelet reactivity on treatment with clopidogrel

Area of Science:

• Pharmacology
• Clinical Medicine
• Genetics

Background:

• Clopidogrel is an antithrombotic agent targeting the P2Y12 receptor.
• Significant interindividual variability in patient response to clopidogrel is well-documented.
• Approximately one-third of patients show high on-treatment platelet reactivity.

Purpose of the Study:

• To address the variability in clopidogrel response.
• To evaluate the potential of tailored treatment strategies based on laboratory tests.
• To discuss the clinical utility and cost-effectiveness of monitoring clopidogrel therapy.

Main Methods:

• Review of existing studies on clopidogrel response variability.
• Analysis of factors influencing clopidogrel absorption and metabolism (prodrug activation).
• Discussion of laboratory tests for platelet function monitoring.

Main Results:

• Genetic and environmental factors contribute to clopidogrel's variable bioavailability and metabolism.
• High on-treatment platelet reactivity is a common issue in patients treated with clopidogrel.
• The ideal laboratory test and clinical utility of monitoring require further investigation.

Conclusions:

• Monitoring clopidogrel therapy requires identification of optimal laboratory tests and validation of clinical utility and cost-effectiveness.
• Alternative antithrombotic drugs with predictable bioavailability and favorable risk/benefit profiles may be preferred.
• Personalized medicine approaches for clopidogrel require further research before widespread clinical adoption.